Spots Global Cancer Trial Database for PSA Antibody Levels in Samples From Patients With Prostate Cancer Treated on Protocol ECOG-E9802

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: PSA Antibody Levels in Samples From Patients With Prostate Cancer Treated on Protocol ECOG-E9802

Official Title: Evaluation of PSA Antibody on E9802: Confirmation and Concordance

Study ID: NCT01672905

Conditions

Prostate Cancer

Interventions

laboratory biomarker analysis

Study Description

Brief Summary: RATIONALE: Studying samples of blood or tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This clinical trial studies prostate-specific antigen (PSA) antibody levels in samples from patients treated for prostate cancer on trial ECOG-E9802.

Detailed Description: OBJECTIVES: Primary * To evaluate changes in prostate-specific antigen (PSA) antibody levels over time among patients treated on ECOG-E9802. Secondary * To characterize the concordance of PSA antibody assessment between the ECOG Immunology Laboratory and the NCI Immunology Laboratory. OUTLINE: Previously tested samples are evaluated for changes in PSA antibody levels over time (from baseline to follow-up at 12 and 24 weeks) at the ECOG Immunology Laboratory and the NCI Immunology Laboratory. Results are compared between the laboratories.